Search information pages
About Clinical and Molecular Allergy
This page includes information about the aims and scope of Clinical and Molecular Allergy, editorial policies, open access and article-processing charges, the peer review process and other information. For details of how to prepare and submit a manuscript through the online submission system, please see the instructions for authors.
Aims & scope
Clinical and Molecular Allergy publishes research on all clinical and molecular aspects of allergic (Type 1 hypersensitivity) and primary immunodeficiency disorders (diseases that alter host defense but are not related to Human Immunodeficiency Virus infection). Studies of allergic or hypersensitive aspects of HIV infection/AIDS or drug desensitization protocols in AIDS, however, fall into the journal’s scope.
Clinical and Molecular Allergy is an open access, peer-reviewed, online journal that publishes research on human allergic and immunodeficient disease (immune deficiency not related to HIV infection/AIDS). The scope of the journal encompasses all aspects of the clinical, genetic, molecular and inflammatory aspects of allergic-respiratory (Type 1 hypersensitivity) and non-AIDS immunodeficiency disorders. However, studies of allergic/hypersensitive aspects of HIV infection/AIDS or drug desensitization protocols in AIDS are acceptable.
At the basic science level, this includes original work and reviews on the genetic and molecular mechanisms underlying the inflammatory response (inflammatory cell function, elaboration of mediators and cell-cell signaling). The journal also considers studies of novel diagnostic and therapeutic approaches to allergic (Type 1 hypersensitivity) and non-AIDS immunodeficiency disorders. These include but are not limited to the use of monoclonal antibodies, immunomodulatory (intravenous immunoglobulin and biological response modifiers) and cytokine- or gene-based therapies.
All articles published by Clinical and Molecular Allergy are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.
Authors of articles published in Clinical and Molecular Allergy are the copyright holders of their articles and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate the article, according to the BioMed Central copyright and license agreement.
Open access publishing is not without costs. Clinical and Molecular Allergy therefore levies an article-processing charge of £1115/$1685/€1305 for each article accepted for publication. We routinely waive charges for authors from low-income countries. Generally, if the submitting author's institution is a Member the cost of the article-processing charge is covered by the membership, and no further charge is payable. In the case of authors whose institutions are Supporter Members, however, a discounted article-processing charge is payable by the author. For further details, see our article-processing charge page. A limited number of waivers for article-processing charges are also available at the editors' discretion, and authors wishing to apply for these waivers should contact the editors.
All articles published in Clinical and Molecular Allergy are included in PubMed, the most widely used biomedical bibliographic database service, which is run by the US National Library of Medicine. Other bibliographic databases that index articles published in Clinical and Molecular Allergy include:
- Global Health
- Google Scholar
- Index Copernicus
- PubMed Central
The full text of all research articles is deposited in PubMed Central, the US National Library of Medicine's full-text repository of life science literature, and other digital archives including e-Depot (The Netherlands).
Clinical and Molecular Allergy has an unofficial Impact Factor of 1.85. BioMed Central is working with Thomson Reuters (ISI) to ensure that citation analysis of articles published in Clinical and Molecular Allergy will be available.
Publication and peer review process
Clinical and Molecular Allergy considers the following types of articles:
- Research - reports of data from original clinical or basic research that provide an insight into the mechanisms governing the allergic response.
- Case reports - reports of clinical cases that provide molecular insights into and/or mechanisms governing common or rare diseases.
- Reviews - comprehensive, authoritative descriptions of any subject within the journal's scope; including timely topics in allergy that will cover the clinical as well as the molecular, etiopathogenic aspects of clinical allergic disease.
- Commentaries - short, focused and opinionated articles on current issues regarding the molecular pathogenesis and management of allergic disease.
- Correspondences- these can take three forms: a substantial re-analysis of a previously published article, or a substantial response to such a re-analysis from the authors of the original publication, or an article that may not cover 'standard research' but that may be relevant to readers.
Peer review in Clinical and Molecular Allergy is designed to ensure that published articles are scientifically sound. Submitted manuscripts will be sent to two external experts for evaluation for scientific significance and validity. Peer reviewers will have three possible options for each manuscript: accept, accept with revision, and reject. Peer reviewers are asked to justify their decision. Based on the critiques of the reviewers, the authors may choose to revise their manuscript and resubmit it for an additional review. Clinical and Molecular Allergy allows authors a maximum of two revisions of a manuscript.
Edited by David S Chi and Guha Krishnaswamy, Clinical and Molecular Allergy is supported by an expert Editorial Board.
Authors will be able to check the progress of their manuscript through the submission system at any time by logging into My Clinical and Molecular Allergy, a personalized section of the site.
High-quality, bound reprints can be purchased for all articles published. Please see our reprints website for further information about ordering reprints.
Clinical and Molecular Allergy will consider supplements based on proceedings (full articles or meeting abstracts), reviews or research. All articles submitted for publication in supplements are subject to peer review. Published supplements are fully searchable and freely accessible online and can also be produced in print. All full length articles (proceedings, reviews or research articles) are indexed by PubMed. PubMed displays the title of the supplement only in the case of meeting abstract collections. For further information, please contact us.
All manuscripts submitted to CMA should adhere to BioMed Central's editorial policies.
Citing articles in Clinical and Molecular Allergy
Articles in Clinical and Molecular Allergy should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.
Article citations follow this format:
Authors: Title. Clin Mol Allergy [year], [volume number]:[article number].
e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Clin Mol Allergy 2009, 1:115.
refers to article 115 from Volume 1 of the journal.
Why publish your article in Clinical and Molecular Allergy?
Clinical and Molecular Allergy's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience. Articles that have been especially highly accessed are highlighted with a 'Highly accessed' graphic, which appears on the journal's contents pages and search results.
Speed of publication
Clinical and Molecular Allergy offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles are published with their final citation immediately upon acceptance in a provisional PDF form. The article will subsequently be published in both fully browsable web form, and as a formatted PDF; the article will then be available through Clinical and Molecular Allergy, BioMed Central and PubMed Central and will also be included in PubMed.
Online publication in Clinical and Molecular Allergy gives authors the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other papers).
Promotion and press coverage
Articles published in Clinical and Molecular Allergy are included in article alerts and regular email updates. Some may be included in abstract books mailed to academics and are highlighted on Clinical and Molecular Allergy's pages and on the BioMed Central homepage.
In addition, articles published in Clinical and Molecular Allergy may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Clinical and Molecular Allergy. A list of articles recently press-released by journals published by BioMed Central is available here.
Authors of articles published in Clinical and Molecular Allergy retain the copyright of their articles and are free to reproduce and disseminate their work (for further details, see the BioMed Central copyright and license agreement).
For further information about the advantages of publishing in a journal from BioMed Central, please click here.